Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.
Daniel C. Danila, MD
Advertisement
Articles by Daniel C. Danila, MD
Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.
Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.
Advertisement
Latest Updated Articles
Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPCPublished: August 10th 2021 | Updated:
Dr. Danila on the Integration of Advanced Imaging in Prostate CancerPublished: August 9th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5